Barinthus Biotherapeutics plc (NASDAQ:BRNS – Get Free Report) was the target of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 11,300 shares, a drop of 19.9% from the February 13th total of 14,100 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 38,300 shares, the days-to-cover ratio is presently 0.3 days.
Analysts Set New Price Targets
Separately, HC Wainwright decreased their price objective on Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Monday, January 13th.
View Our Latest Stock Report on Barinthus Biotherapeutics
Institutional Inflows and Outflows
Barinthus Biotherapeutics Stock Down 1.9 %
BRNS stock opened at $1.04 on Tuesday. The business has a 50 day moving average price of $1.02 and a 200 day moving average price of $1.13. The stock has a market cap of $41.84 million, a price-to-earnings ratio of -0.70 and a beta of -0.80. Barinthus Biotherapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $4.16.
Barinthus Biotherapeutics Company Profile
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
Read More
- Five stocks we like better than Barinthus Biotherapeutics
- How to Calculate Stock Profit
- Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
- What Are the U.K. Market Holidays? How to Invest and Trade
- 2 Shorted Stocks Under Fire: Do Bulls or Bears Have It Right?
- Stock Average Calculator
- Is Intuitive Machines a Buy After Athena’s Disappointing Landing?
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.